135.83
price up icon2.26%   3.00
after-market Dopo l'orario di chiusura: 133.76 -2.07 -1.52%
loading
Precedente Chiudi:
$132.83
Aprire:
$133.62
Volume 24 ore:
124.87K
Relative Volume:
0.89
Capitalizzazione di mercato:
$2.62B
Reddito:
$152.42M
Utile/perdita netta:
$45.24M
Rapporto P/E:
54.12
EPS:
2.51
Flusso di cassa netto:
$6.97M
1 W Prestazione:
-2.35%
1M Prestazione:
+17.38%
6M Prestazione:
+18.08%
1 anno Prestazione:
+28.13%
Intervallo 1D:
Value
$132.59
$135.83
Intervallo di 1 settimana:
Value
$131.75
$143.13
Portata 52W:
Value
$90.29
$143.13

Ligand Pharmaceuticals Inc Stock (LGND) Company Profile

Name
Nome
Ligand Pharmaceuticals Inc
Name
Telefono
858-550-7500
Name
Indirizzo
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Name
Dipendente
68
Name
Cinguettio
@Ligand_LGND
Name
Prossima data di guadagno
2025-02-18
Name
Ultimi documenti SEC
Name
LGND's Discussions on Twitter

Confronta LGND con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
LGND
Ligand Pharmaceuticals Inc
135.83 2.56B 152.42M 45.24M 6.97M 2.51
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-10 Iniziato Stifel Buy
2024-10-03 Iniziato Oppenheimer Outperform
2024-07-30 Iniziato RBC Capital Mkts Outperform
2021-04-14 Ripresa Stephens Overweight
2021-02-04 Reiterato H.C. Wainwright Buy
2020-10-06 Iniziato Barclays Overweight
2020-03-24 Downgrade Argus Buy → Hold
2020-03-10 Iniziato Guggenheim Neutral
2020-02-06 Iniziato The Benchmark Company Buy
2019-09-19 Aggiornamento Barclays Equal Weight → Overweight
2019-06-11 Iniziato Barclays Equal Weight
2019-05-03 Reiterato H.C. Wainwright Buy
2019-03-06 Reiterato H.C. Wainwright Buy
2018-10-29 Aggiornamento ROTH Capital Neutral → Buy
2018-10-02 Reiterato H.C. Wainwright Buy
2018-09-11 Reiterato Argus Buy
2018-08-17 Iniziato Goldman Neutral
2018-08-08 Downgrade ROTH Capital Buy → Neutral
2018-06-21 Iniziato Argus Buy
2017-12-27 Reiterato H.C. Wainwright Buy
2017-09-05 Ripresa H.C. Wainwright Buy
2016-10-05 Reiterato H.C. Wainwright Buy
2016-08-05 Downgrade Deutsche Bank Hold → Sell
2016-03-11 Iniziato Sidoti Buy
2016-03-03 Iniziato H.C. Wainwright Buy
Mostra tutto

Ligand Pharmaceuticals Inc Borsa (LGND) Ultime notizie

pulisher
01:25 AM

Ligand Pharmaceuticals Incorporated Stock Analysis and ForecastHigh-margin investment plays - PrintWeekIndia

01:25 AM
pulisher
07:45 AM

What drives Ligand Pharmaceuticals Incorporated stock priceBreakout portfolio performance - Autocar Professional

07:45 AM
pulisher
Jul 24, 2025

Mark Your Calendar: Ligand Q2 2025 Earnings Report Coming August 7Key Details Inside - Stock Titan

Jul 24, 2025
pulisher
Jul 23, 2025

What analysts say about Ligand Pharmaceuticals Incorporated stockExceptional trading performance - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

Is Ligand Pharmaceuticals Incorporated a good long term investmentHigh-velocity capital appreciation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 18, 2025

Is Ligand Pharmaceuticals Incorporated stock a growth or value playFree Capital Allocation Plans - beatles.ru

Jul 18, 2025
pulisher
Jul 18, 2025

Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND) and Sarepta Therapeutics (SRPT) - The Globe and Mail

Jul 18, 2025
pulisher
Jul 17, 2025

Stifel reiterates Buy rating on Ligand Pharma stock at $143 price target - Investing.com Canada

Jul 17, 2025
pulisher
Jul 17, 2025

Teacher Retirement System of Texas Has $534,000 Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Jul 17, 2025
pulisher
Jul 16, 2025

Ligand Pharmaceuticals stock hits 52-week high at 130.0 USD - Investing.com Australia

Jul 16, 2025
pulisher
Jul 16, 2025

Ligand Pharmaceuticals stock hits 52-week high at 130.0 USD By Investing.com - Investing.com Nigeria

Jul 16, 2025
pulisher
Jul 15, 2025

What makes Ligand Pharmaceuticals Incorporated stock price move sharplyHigh Yield Opportunities - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Ligand Pharmaceuticals Incorporated stock performs during market volatilityFree Real-Time Trading Opportunities - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Ligand Pharmaceuticals Incorporated stock attracts strong analyst attentionFree Access to Community - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Craig-Hallum Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Announces Target Price $140 - 富途牛牛

Jul 15, 2025
pulisher
Jul 14, 2025

Principal Financial Group Inc. Acquires 3,284 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Jul 14, 2025
pulisher
Jul 11, 2025

Insider Sell Alert: John Kozarich Sells Shares of Ligand Pharmac - GuruFocus

Jul 11, 2025
pulisher
Jul 11, 2025

Ligand Pharmaceuticals director Kozarich sells $116k in stock By Investing.com - Investing.com South Africa

Jul 11, 2025
pulisher
Jul 11, 2025

Ligand Pharmaceuticals director Kozarich sells $116k in stock - Investing.com Australia

Jul 11, 2025
pulisher
Jul 11, 2025

Ligand Pharmaceuticals Director John Kozarich Sells 934 Shares at $125/Share. - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

Amalgamated Bank Has $564,000 Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Jul 11, 2025
pulisher
Jul 11, 2025

Ligand earns $5 million milestone as partner launches molluscum treatment By Investing.com - Investing.com South Africa

Jul 11, 2025
pulisher
Jul 10, 2025

Ligand Pharmaceuticals (LGND) Soars 2.11% on ZELSUVMI Launch, Milestone Payment - AInvest

Jul 10, 2025
pulisher
Jul 10, 2025

Pelthos Therapeutics shares rise 1.27% in after-hours after commercial launch of ZELSUVMI™ and merger with Channel Therapeutics. - AInvest

Jul 10, 2025
pulisher
Jul 10, 2025

Pelthos, Ligand Gain After Launch Of First Prescription-At-Home Treatment For Water Warts - Stocktwits

Jul 10, 2025
pulisher
Jul 10, 2025

ZELSUVMI's FDA Approval: A Breakthrough for Pelthos and a Windfall for Ligand? - AInvest

Jul 10, 2025
pulisher
Jul 10, 2025

ZELSUVMI Launch Positions Ligand Pharmaceuticals for Growth in a Booming Skin Care Market - AInvest

Jul 10, 2025
pulisher
Jul 10, 2025

Ligand earns $5 million milestone as partner launches molluscum treatment - Investing.com

Jul 10, 2025
pulisher
Jul 10, 2025

Ligand Partner Pelthos Therapeutics Launches ZELSUVMI - MarketScreener

Jul 10, 2025
pulisher
Jul 10, 2025

Ligand Pharmaceuticals Partner Pelthos Launches Molluscum Contagiosum Treatment Zelsuvmi - MarketScreener

Jul 10, 2025
pulisher
Jul 10, 2025

Ligand (LGND) Advances with Successful Launch of ZELSUVMI Gel | - GuruFocus

Jul 10, 2025
pulisher
Jul 10, 2025

Ligand Pharmaceuticals Partner Pelthos Therapeutics Launches ZELSUVMI™ for Molluscum Contagiosum Treatment - Quiver Quantitative

Jul 10, 2025
pulisher
Jul 10, 2025

Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™ - GlobeNewswire

Jul 10, 2025
pulisher
Jul 10, 2025

Breakthrough: First-Ever At-Home Treatment for Molluscum LaunchesLigand Secures $5M Milestone Payment - Stock Titan

Jul 10, 2025
pulisher
Jul 09, 2025

GAMMA Investing LLC Has $62,000 Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Jul 09, 2025
pulisher
Jul 05, 2025

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Average Recommendation of “Buy” from Analysts - Defense World

Jul 05, 2025
pulisher
Jul 03, 2025

Ligand’s LNHC concludes merger with CHRO - Yahoo Finance

Jul 03, 2025
pulisher
Jul 02, 2025

Ligand Pharma Completes Merger Forming Pelthos Therapeutics - TipRanks

Jul 02, 2025
pulisher
Jul 02, 2025

Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics - The Manila Times

Jul 02, 2025
pulisher
Jul 02, 2025

Pelthos Therapeutics to Launch ZELSUVMI™ for Molluscum Contagiosum in July 2025 Following Merger with Ligand Pharmaceuticals - Quiver Quantitative

Jul 02, 2025
pulisher
Jul 02, 2025

Ligand completes merger, Pelthos to launch molluscum treatment - Investing.com

Jul 02, 2025

Ligand Pharmaceuticals Inc Azioni (LGND) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Capitalizzazione:     |  Volume (24 ore):